Skip Navigation

Link to  the National Institutes of Health  
The Science of Drug Abuse and Addiction from the National Institute on Drug Abuse Archives of the National Institute on Drug Abuse web site
Go to the Home page

NIDA Home > Publications > Director's Reports > February, 2010 Index    

Director's Report to the National Advisory Council on Drug Abuse - February, 2010

Extramural Policy and Review Activities

Receipt, Referral, and Review

NIDA received 1,205 applications, including both primary and dual assignments, for which the Office of Extramural Affairs (OEA) managed the programmatic referral process during this Council cycle. Of these, NIDA received the primary assignment on 819 applications.

OEA arranged and managed 14 grant review meetings in which 183 applications were evaluated. OEA's reviews included applications in chartered, standing review committees and Special Emphasis Panels (SEPs). In addition, OEA's Contracts Review Branch (CRB) arranged and managed 15 contract proposal review meetings.

NIDA's chartered committees consist of NIDA-F (Health Services Review Committee), NIDA-L (Medications Development Committee), and NIDA-K (Training Committee). Applications that formerly were assigned to NIDA E (Treatment Review Committee) are now reviewed in CSR. This review cycle also marked the last meetings of NIDA-F and NIDA-L; starting with applications being reviewed for the May 2010 Council, CSR will review applications in the scientific areas that had been assigned to these two committees.

In addition to meetings of the chartered committees, OEA staff held 11 Special Emphasis Panels to review grant applications for a variety of reasons:

  • Conflicts with the chartered committees
  • Cutting-Edge Basic Research Awards (CEBRA)
  • Behavioral Science Track Award for Rapid Transition (B/START)
  • Imaging Science Track Award for Research Transition (I/START)
  • Conference Grants (R13)
  • Requests for Applications (RFAs)

OEA managed the following RFA reviews:

  • DA10-003 - Integrating Translational Neuroscience and Adolescent Drug Abuse Treatment (R21)
  • DA10-004 - Economic Studies of Health Insurance Coverage on Drug Abuse Treatment Availability, Access, Costs, and Quality (R01)

Completed contract-related review activity from the Contracts Review Branch since the last Council includes:

R&D and non-R&D Contract Reviews

  • NO1DA10-9913 - Out Patient Drug Treatment Research Clinic
  • N01DA-10-7773 - Production, Analysis, and Distribution of Cannabis, Marijuana Cigarettes, and related Materials

Phase I SBIR Contract Reviews

  • N43 DA10-2218 - New Technologies: Integrating Data from Prescription Monitoring Program(s) to Current Clinical Practice
  • N43 DA10-2219 - Development of Innovative Techniques/Tools for the Screening, Recruitment and Follow-up of Clinical Trial Participants
  • N43 DA10-2220 - Innovative Diagnostic Drug Screening Tests for Drugs of Abuse
  • N43 DA10-4412 - Web Based Cognitive/Neuropsychological testing for Substance Abuse
  • N43 DA10-5558 - Development of State-of-the-Art Mechanisms for Epidemiological Records
  • N43 DA10-5559 - Using Handheld Devices to Support Recovery
  • N43 DA10-5560 - Tools to Promote Security and Appropriate Prescribing of Scheduled Prescription Drugs
  • N43 DA10-5561 - Marketing Evidence-Based Prevention Interventions for Substance Abuse Prevention
  • N43 DA10-7774 - Rapid and Sensitive Method for the Determination of Nicotine & its Major Cotinine and trans-3'-hydroxycotinine, in Biological Fluids: A Personalized Medicine Approach for Smoking Cessation
  • N43 DA10-7775 - Tool Development for New or Improved Capture Reagents
  • N43 DA10-7776 - Development of Alternate Drug Delivery Dosage Forms for Drug Studies
  • N43 DA10-8892 - Design and Synthesis of Treatment Agents for Drug Abuse
  • N43 DA10-8893 - Pharmaceutical Approaches for Development of Pharmacotherapies for Drug Addiction

Certificates of Confidentiality

Between August 11, 2009 and January 4, 2010, OEA processed 149 Certificate of Confidentiality applications, including 27 amendments for either extension of expiration date or protocol change.

Staff Training and Development

The OEA Symposium Series, a forum for staff training and sharing of ideas and information, continued to provide open forums for discussions and presentations that included: The NIH Public-Private Partnership Program and the Foundation of the National Institutes of Health (Barbara Mittleton, MD, Director PPPP; Ann Ashby, Deputy Director Foundation for NIH, Andrea Baruchin, Associate Director Foundation for NIH); NIH/NSF Collaborations (Josh Rosenthal, FIC); NIH Staff training on implementing the Enhancing Peer Review changes; All Things SBIR (Jerry McLaughlin, OEA; Catherine Sasek, OSPC; Craig Sager, CMB; Diana Haikalis, GMB); and NIH Scientific Publication Information Retrieval and Evaluation System (SPIRES; Paul Jordan, eRA).

CTN-Related Review Activities

The Protocol Review Board met on September 14, 2009 to review the study proposal CTN 0047, Screening, Motivational Assessment, Referral and Treatment in Emergency Departments (SMART-ED).

The Data and Safety Monitoring Board(s) met:

  • October 6, 2009 to discuss the final study report for study CTN 0028, Randomized Controlled Trial of Osmotic-Release Methylphenidate (OROS MPH) for Attention Deficit Hyperactivity Disorder (ADHD) in Adolescents with Substance Use Disorders (SUD)
  • October 19, 2009, to discuss study protocols CTN 0027, Starting Treatment with Agonist Replacement Therapies (START) and CTN 0031, Stimulant Abuser Groups to Engage in 12-Step (STAGE-12).


Research Findings

Program Activities

Extramural Policy and Review Activities

Congressional Affairs

International Activities

Meetings and Conferences

Media and Education Activities

Planned Meetings


Staff Highlights

Grantee Honors

Archive Home | Accessibility | Privacy | FOIA (NIH) | Current NIDA Home Page
National Institutes of Health logo_Department of Health and Human Services Logo The National Institute on Drug Abuse (NIDA) is part of the National Institutes of Health (NIH) , a component of the U.S. Department of Health and Human Services. Questions? See our Contact Information. The U.S. government's official web portal